Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge
about
Side-by-side comparison of gene-based smallpox vaccine with MVA in nonhuman primatesStructural and Biochemical Characterization of the Vaccinia Virus Envelope Protein D8 and Its Recognition by the Antibody LA5Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agentsAn influenza A/H1N1/2009 hemagglutinin vaccine produced in Escherichia coliSublingual administration of bacteria-expressed influenza virus hemagglutinin 1 (HA1) induces protection against infection with 2009 pandemic H1N1 influenza virus.A baseline process for the production, recovery, and purification of bacterial influenza vaccine candidates.The immunology of smallpox vaccines.Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens.A recombinant flagellin-poxvirus fusion protein vaccine elicits complement-dependent protection against respiratory challenge with vaccinia virus in miceSoluble recombinant human metapneumovirus G protein is immunogenic but not protective.A protein-based smallpox vaccine protects non-human primates from a lethal monkeypox virus challenge.Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administration.Impact of ST-246® on ACAM2000™ smallpox vaccine reactogenicity, immunogenicity, and protective efficacy in immunodeficient mice.Effect of vaccination with modified vaccinia Ankara (ACAM3000) on subsequent challenge with Dryvax.Smallpox vaccines: targets of protective immunity.Multivalent smallpox DNA vaccine delivered by intradermal electroporation drives protective immunity in nonhuman primates against lethal monkeypox challenge.Protection against multiple influenza A virus strains induced by candidate recombinant vaccine based on heterologous M2e peptides linked to flagellin.Parainfluenza virus 5-based vaccine vectors expressing vaccinia virus (VACV) antigens provide long-term protection in mice from lethal intranasal VACV challenge.Polyclonal antibody cocktails generated using DNA vaccine technology protect in murine models of orthopoxvirus disease.Measurement of antibody responses to Modified Vaccinia virus Ankara (MVA) and Dryvax(®) using proteome microarrays and development of recombinant protein ELISAsStructural and Functional Characterization of Anti-A33 Antibodies Reveal a Potent Cross-Species Orthopoxviruses Neutralizer.Single-shot immunization with recombinant adenovirus encoding vaccinia virus glycoprotein A27L is protective against a virulent respiratory poxvirus infection.Development of a Genus-Specific Antigen Capture ELISA for Orthopoxviruses - Target Selection and Optimized ScreeningRecombinant antibodies for diagnostics and therapy against pathogens and toxins generated by phage display.Generation of Recombinant Antibodies Against Toxins and Viruses by Phage Display for Diagnostics and Therapy.Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice.Disparity between levels of in vitro neutralization of vaccinia virus by antibody to the A27 protein and protection of mice against intranasal challenge.Engineering the vaccinia virus L1 protein for increased neutralizing antibody response after DNA immunization.The heterogeneity of human antibody responses to vaccinia virus revealed through use of focused protein arrays.Immunogenicity of recombinant Modified Vaccinia Ankara following a single or multi-dose vaccine regimen in rhesus monkeys.ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestationSerro 2 Virus Highlights the Fundamental Genomic and Biological Features of a Natural Vaccinia Virus Infecting Humans.The strategic use of novel smallpox vaccines in the post-eradication world.Defending against smallpox: a focus on vaccines.Porcine Dendritic Cells as an In Vitro Model to Assess the Immunological Behaviour of Streptococcus suis Subunit Vaccine Formulations and the Polarizing Effect of Adjuvants.Recombinant Sheep Pox Virus Proteins Elicit Neutralizing AntibodiesGeneration of an attenuated Tiantan vaccinia virus by deletion of the ribonucleotide reductase large subunit.Protection of Mice from Lethal Vaccinia Virus Infection by Vaccinia Virus Protein Subunits with a CpG Adjuvant.
P2860
Q27325586-9EA18BFF-97F6-4BF0-8F1D-286592D341DDQ27679281-73B526C7-8EBF-4CDD-AEC3-5E8B48743E23Q28384852-5A4B4C37-A7E7-46ED-A4B4-355C831F7EEBQ28750246-5AC22C22-5394-4826-A8DA-EC33526A2C7EQ30427778-22C6F702-7341-4B80-9E63-0C0DF3B06DF5Q30431659-D7BFC09F-6988-4340-96F1-97E7816F26F7Q33679943-1291AFB3-E010-4194-A119-AA952ECD3396Q33725635-CC913AB5-AE66-4316-A523-D658246D50EBQ33905188-E1BDE2F6-4BCE-4C0A-A0AA-5E8C495622AAQ33950358-B5B9B910-99BB-4E16-BBBC-A235645521D3Q34126697-185B7D33-CFAA-4F29-AFAD-F01B8A891818Q34470311-6FDAC9AB-B5C4-4A0E-A690-7F70763BF546Q34502253-F662FA42-1F90-4EAA-ACBC-890F009852A1Q34502997-4C5EB40E-95F7-49A0-A453-BB20C7F3C456Q34780607-0EFC5626-2291-47F9-9AC0-DDAC5D075945Q34910424-2709D5A7-FB62-49CD-9DBA-DDCBB16E7BDFQ35209148-B33DDCFE-FAD7-4E3D-BC97-92E080AB68CBQ35226200-6CFCBEB7-2FDA-4F41-BD05-CF5BD7890295Q35339702-4E0B44CE-BD95-4CAB-A3FA-F4099B633BFDQ35634159-118D57B9-C6C4-4231-8AE1-CE4606E6098EQ35760869-A1303625-41FF-4966-884C-C05044E4CDE7Q35830974-D6B054BE-2DC8-4B5E-B61A-273FBD8CFCA0Q35941208-528FEB42-1416-4DB4-9291-62F423AAE814Q36023082-C98A3047-E92D-4003-8AD7-F85303A94423Q36033286-85705E6D-7A65-411F-BB0F-56248647786CQ36747784-53A4388D-9F69-4274-950D-C37B5FD12247Q36845650-E9B174E9-761D-48F5-8430-4ECE3498DBEFQ37125302-0DD95B6A-4DE7-4BEC-BB9C-880BEF3CAF89Q37169163-12021FEE-34AA-44EE-AE61-FC973F40AB56Q37174356-BB930C64-B9E6-4C6B-9600-816CB5A26297Q37450819-0942D4D0-469D-477E-9F35-907D19EDF2D1Q37539293-179096E3-E259-4812-8A15-81171992F2F0Q37909421-F75B4033-3917-4B3E-A60A-93C006451613Q38799357-B256B582-FE3F-47CC-A514-310CCEDEEFD1Q40284594-5EEBCFAD-9731-4D53-B826-DEF3D6036698Q40684847-60D755B5-3263-4325-BDC8-26AD76395BD7Q42221766-EDF402F4-2B6B-457C-8EF0-1E750E54453BQ47155945-74CB7FA1-3929-4A17-B20F-6B1E1E3FD269
P2860
Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Vaccination of BALB/c mice wit ...... ethal vaccinia virus challenge
@ast
Vaccination of BALB/c mice wit ...... ethal vaccinia virus challenge
@en
type
label
Vaccination of BALB/c mice wit ...... ethal vaccinia virus challenge
@ast
Vaccination of BALB/c mice wit ...... ethal vaccinia virus challenge
@en
prefLabel
Vaccination of BALB/c mice wit ...... ethal vaccinia virus challenge
@ast
Vaccination of BALB/c mice wit ...... ethal vaccinia virus challenge
@en
P2093
P2860
P356
P1433
P1476
Vaccination of BALB/c mice wit ...... ethal vaccinia virus challenge
@en
P2093
Aklile Berhanu
Alex K Krupkin
Dana L Kirkwood-Watts
David S King
Dennis E Hruby
Douglas W Grosenbach
Erin Vandermay
Kady M Honeychurch
Kevin F Jones
Lindsay L Brown
P2860
P304
P356
10.1128/JVI.01854-07
P407
P577
2008-01-16T00:00:00Z